Phenylthiocarbamide perception in patients with schizophrenia and first-degree family members
Phenylthiocarbamide perception in patients with schizophrenia and first-degree family members
复制标题
DOI：
10.1176/appi.ajp.162.4.788
复制
发表时间：
2005-04-01
影响因子：
17.7
通讯作者：
Turetsky, BI
中科院分区：
文献类型：
--
作者：
Moberg, PJ;Roalf, DR;Turetsky, BI
目的：无法品尝苯硫脲（PTC）与通常与味觉无关的医学和神经疾病有关。研究PTC敏感性在精神分裂症患者和他们的非患病亲属，以确定这是否代表一个脆弱marker.Method：PTC敏感性进行了评估，在42例精神分裂症患者，23名健康对照组，和12名一级亲属的patient.Results：更多的nontasters被发现在患者和家庭成员比健康对照组。在患者中，味觉缺失者有更多的阳性症状。性别，年龄，药物治疗，吸烟，或cognitive impairment.Conclusions：PTC nontasters的患病率是更大的精神分裂症患者和非患病的第一学位的家庭成员。PTC敏感性的表型变异起源于遗传。这表明具有隐性等位基因的受试者患病的风险更高。
Objective: The inability to taste phenylthiocarbamide (PTC) has been associated with medical and neurological illnesses not typically related to taste. The authors examined PTC sensitivity in schizophrenia patients and their non-ill relatives to determine whether this represented a vulnerability marker.Method: PTC sensitivity was assessed in 42 schizophrenia patients, 23 healthy comparison subjects, and 12 first-degree relatives of the patients.Results: More nontasters were found among patients and family members than healthy comparison subjects. Among patients, nontasters had more positive symptoms. Differences were not explained by sex, age, medication, smoking, or cognitive impairment.Conclusions: The prevalence of PTC nontasters was greater among schizophrenia patients and non-ill first-degree family members. Phenotypic variation in PTC sensitivity is genetic in origin. This suggests a higher risk for illness among subjects with recessive alleles.